IQWiG: GSK's antidiabetic Eperzan hints at minor benefit
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's Eperzan (albiglutide) has a "hint of minor additional benefit" for one indication compared to competitors, according to IQWiG, Germany's health technology appraisal body.